Efg Asset Management (North America) Corp. Bei Gene, Ltd. Transaction History
Efg Asset Management (North America) Corp.
- $585 Million
- Q3 2024
A detailed history of Efg Asset Management (North America) Corp. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 13,475 shares of BGNE stock, worth $2.95 Million. This represents 0.52% of its overall portfolio holdings.
Number of Shares
13,475
Previous 17,780
24.21%
Holding current value
$2.95 Million
Previous $2.54 Million
19.28%
% of portfolio
0.52%
Previous 0.45%
Shares
6 transactions
Others Institutions Holding BGNE
# of Institutions
253Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.31 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.41 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.13 Billion26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$1.09 Billion0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$810 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $22.7B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...